a study of atezolizumab in combination with either obinutuzumab plus bendamustine or obinutuzumab plus (+) cyclophosphamide, doxorubicin, vincristine, and prednisone (chop) in participants with follicular lymphoma (fl) or rituximab + chop in participants with diffuse large b-cell lymphoma (dlbcl)

Conditions: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

Summary: this phase ib/ii, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment consisting of atezolizumab in combination with either obinutuzumab + bendamustine (atezo-g-benda) or obinutuzumab + chop (atezo-g-chop) in participants with fl and atezolizumab + rituximab + chemotherapy (atezo-r-chop) in participants with dlbcl, followed by post-induction treatment consisting of either atezolizumab plus obinutuzumab (atezo-g) in participants with fl who achieve a complete response (cr) or partial response (pr) at end of induction (eoi) or atezolizumab alone in participants with dlbcl who achieve a cr at eoi.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * for participants enrolled in the safety run-in phase: lymphoma classified as either relapsed or refractory fl after treatment with at least one prior chemoimmunotherapy regimen or previously untreated grade 1, 2, or 3a fl that requires treatment * for participants enrolled in the expansion phase: lymphoma classified as either previously untreated grade 1, 2, or 3a fl that requires treatment or previously untreated advanced dlbcl * histologically documented cluster of differentiation 20 (cd20) positive lymphoma * fluorodeoxyglucose-avid lymphoma * at least one bi-dimensionally measurable lesion (greater than \[\>\] 1.5 centimeters in its largest dimension by ct scan or magnetic resonance imaging) * availability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of fl or dlbcl * for women who are not postmenopausal or surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than \[\<\] 1 percent \[%\] per year during the treatment period and for at least 18 months after the last dose of study treatment for participants in the atezo-g-benda and atezo-g-chop treatment groups or for at least 12 months after the last dose of study treatment for participants in the atezo-r-chop treatment group * for men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm exclusion criteria: * histological evidence of transformation of fl into high-grade b-cell non-hodgkin's lymphoma (nhl) * central nervous system lymphoma or leptomeningeal infiltration * for participants with dlbcl: preplanned consolidative radiotherapy * treatment with systemic immunosuppressive medications, including, but not limited to, prednisone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to day 1 of cycle 1 * for participants with relapsed or refractory fl: prior allogeneic or autologous stem cell transplantation, anthracycline therapy, treatment with fludarabine or alemtuzumab within 12 months prior to day 1 of cycle 1, treatment with a monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate within 4 weeks prior to day 1 of cycle 1, radiotherapy, chemotherapy, hormonal therapy, or targeted small-molecule therapy within 2 weeks prior to day 1 of cycle 1 * history of solid organ transplantation * history of severe allergic or anaphylactic reaction or known sensitivity to humanized or murine monoclonal antibodies * known hypersensitivity to biopharmaceuticals produced in chinese hamster ovary cells or any component of the atezolizumab, obinutuzumab, rituximab, or bendamustine formulation, including mannitol * positive for hepatitis b surface antigen (hbsag), total hepatitis b core antibody (hbcab), or hepatitis c virus (hcv) antibody at screening * history of progressive multifocal leukoencephalopathy * vaccination with a live virus vaccine within 28 days prior to day 1 of cycle 1 * history of other malignancy, autoimmune disease, or any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results * major surgical procedure other than for diagnosis within 28 days prior to day 1 of cycle 1, or anticipation of a major surgical procedure during the course of the study * for participants who will be receiving chop: left ventricular ejection fraction (lvef) \<50% by multiple-gated acquisition (muga) scan or echocardiogram * inadequate hematologic, renal, and liver function (unless due to underlying lymphoma)